Roh Kyung-Ho, Nerem Robert M, Roy Krishnendu
The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory, Atlanta, Georgia 30332-0313; email:
The Parker H. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, Georgia 30332.
Annu Rev Chem Biomol Eng. 2016 Jun 7;7:455-78. doi: 10.1146/annurev-chembioeng-080615-033559.
Stem cells and other functionally defined therapeutic cells (e.g., T cells) are promising to bring hope of a permanent cure for diseases and disorders that currently cannot be cured by conventional drugs or biological molecules. This paradigm shift in modern medicine of using cells as novel therapeutics can be realized only if suitable manufacturing technologies for large-scale, cost-effective, reproducible production of high-quality cells can be developed. Here we review the state of the art in therapeutic cell manufacturing, including cell purification and isolation, activation and differentiation, genetic modification, expansion, packaging, and preservation. We identify current challenges and discuss opportunities to overcome them such that cell therapies become highly effective, safe, and predictively reproducible while at the same time becoming affordable and widely available.
干细胞和其他功能明确的治疗性细胞（如T细胞）有望为目前无法用传统药物或生物分子治愈的疾病和病症带来永久治愈的希望。只有开发出适用于大规模、经济高效、可重复生产高质量细胞的制造技术，现代医学中这种将细胞用作新型治疗方法的范式转变才能实现。在此，我们综述了治疗性细胞制造的技术现状，包括细胞纯化与分离、激活与分化、基因修饰、扩增、封装和保存。我们确定了当前面临的挑战，并讨论了克服这些挑战的机会，以使细胞疗法变得高效、安全且可预测地重复，同时变得经济实惠且广泛可得。
